You are viewing AANS Neurosurgeon Volume 26, Number 3, 2017. View our current issue, Volume 27, Number 1, 2018

AANS Neurosurgeon | Volume 26, Number 3, 2017

Advertisement

Cannabidiol Reduces Seizures in Children with Severe Epilepsy

Randomized placebo-controlled clinical trial shows decline in seizures with cannabidiol in children with drug-resistant Dravet syndrome

Results from a double-blind, placebo-controlled trial revealed that children with Dravet syndrome, a severe form of epilepsy, had fewer seizures after taking a daily oral solution of the cannabis compound called cannabidiol, which does not have the psychoactive properties of marijuana. Over a 14-week treatment with cannabidiol, convulsive seizures dropped from a monthly average of 12.4 to 5.9. In comparison, seizures in the placebo group decreased from a monthly average of 14.9 to 14.1. During the study, seizures stopped completely in 5 percent of patients taking cannabidiol. “Seizures in Dravet syndrome are extremely difficult to control and they can be deadly,” says study co-author Linda Laux, MD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago. “Our results are encouraging, especially considering that we don’t have any antiepileptic drugs approved for Dravet syndrome in the U.S.”

Click here to read more.

Calendar/Courses

Second International Brain Mapping Course
April 26-27, 2018; New Orleans

Surgical Approaches to Skull Base
April 26-28, 2018; St. Louis, MO

2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans

Comments are closed.